Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 10/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006670 | 0.90 | USP1 (0.40) | USP1P2RX3 | |
| SCHEMBL10008025 | 0.86 | USP1 (0.40) | USP1GRIN1GRIN2B | |
| SCHEMBL10007752 | 0.86 | USP1 (0.38) | USP1GRIN1GRIN2BCACNA1H | |
| SCHEMBL10267773 | 0.84 | DAGLA (0.46) | USP1 | |
| SCHEMBL10007270 | 0.83 | MAOB (0.38) | USP1GRIN1GRIN2B | |
| SCHEMBL10007321 | 0.83 | USP1 (0.42) | USP1GRIN1GRIN2B | |
| SCHEMBL10007172 | 0.81 | USP1 (0.39) | USP1GRIN1GRIN2B | |
| SCHEMBL10007126 | 0.80 | GRIN2B (0.41) | USP1GRIN1GRIN2B | |
| SCHEMBL10006976 | 0.79 | ACACB (0.37) | USP1P2RX3GRIN1GRIN2BCACNA1H | |
| SCHEMBL10006801 | 0.79 | ALDH1A1 (0.39) | USP1GRIN1GRIN2BPDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2476682-A1 | 8-OXODIHYDROPURINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | USP1 1070/4885P2RX3 60/4885GRIN1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.